Trial Profile
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jun 2019
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Novartis
- 23 May 2019 Results published in the Journal of Allergy and Clinical Immunology
- 08 Mar 2016 Primary endpoint has been met. (Percentage of Participants Achieving Skin Histology Response After Secukinumab Treatment From Baseline to Week 12), as per results presented at the 74th Annual Meeting of the American Academy of Dermatology.
- 08 Mar 2016 Results presented at the 74th Annual Meeting of the American Academy of Dermatology